EP2028189A3 - Variants of group 1 allergens made of poaceae with reduced allergenicity and received T-cell reactivity - Google Patents

Variants of group 1 allergens made of poaceae with reduced allergenicity and received T-cell reactivity Download PDF

Info

Publication number
EP2028189A3
EP2028189A3 EP08014111A EP08014111A EP2028189A3 EP 2028189 A3 EP2028189 A3 EP 2028189A3 EP 08014111 A EP08014111 A EP 08014111A EP 08014111 A EP08014111 A EP 08014111A EP 2028189 A3 EP2028189 A3 EP 2028189A3
Authority
EP
European Patent Office
Prior art keywords
allergens
variants
poaceae
group
received
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08014111A
Other languages
German (de)
French (fr)
Other versions
EP2028189A2 (en
Inventor
Helmut Prof. Fiebig
Martin Dr. Wald
Andreas Dr. Nandy
Helga Dr. Kahlert
Bernhard Dr. Weber
Oliver Dr. Cromwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP2028189A2 publication Critical patent/EP2028189A2/en
Publication of EP2028189A3 publication Critical patent/EP2028189A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft die Herstellung und Verwendung von Varianten der Gruppe-1-Allergene der Poaceae (Süßgräser), welche durch eine gegenüber den bekannten Wildtyp-Allergenen verringerte IgE-Reaktivität und gleichzeitig eine weitgehend erhaltene Reaktivität mit T-Lymphozyten gekennzeichnet sind.The present invention relates to the production and use of variants of the group 1 allergens of Poaceae (sweet grasses) which are characterized by reduced IgE reactivity compared to the known wild-type allergens and at the same time a largely retained reactivity with T lymphocytes.

Diese hypoallergenen Allergenvarianten können zur spezifischen Immun-therapie (Hyposensibilisierung) von Patienten mit Gräserpollenallergie oder zur präventiven Immuntherapie von Gräserpollenallergien eingesetzt werden.These hypoallergenic allergen variants can be used for the specific immune therapy (hyposensitization) of patients with grass pollen allergy or for the preventive immunotherapy of grass pollen allergies.

EP08014111A 2004-07-21 2005-07-11 Variants of group 1 allergens made of poaceae with reduced allergenicity and received T-cell reactivity Withdrawn EP2028189A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004035337A DE102004035337A1 (en) 2004-07-21 2004-07-21 Variations of the group 1 allergens from Poaceae with reduced allergenicity and preserved T cell reactivity
EP05761824A EP1768996B1 (en) 2004-07-21 2005-07-11 Variants of group 1 allergens of poaceae with reduced allergenicity and a maintained t-cell reactivity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP05761824A Division EP1768996B1 (en) 2004-07-21 2005-07-11 Variants of group 1 allergens of poaceae with reduced allergenicity and a maintained t-cell reactivity

Publications (2)

Publication Number Publication Date
EP2028189A2 EP2028189A2 (en) 2009-02-25
EP2028189A3 true EP2028189A3 (en) 2009-07-08

Family

ID=35106807

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05761824A Not-in-force EP1768996B1 (en) 2004-07-21 2005-07-11 Variants of group 1 allergens of poaceae with reduced allergenicity and a maintained t-cell reactivity
EP08014111A Withdrawn EP2028189A3 (en) 2004-07-21 2005-07-11 Variants of group 1 allergens made of poaceae with reduced allergenicity and received T-cell reactivity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05761824A Not-in-force EP1768996B1 (en) 2004-07-21 2005-07-11 Variants of group 1 allergens of poaceae with reduced allergenicity and a maintained t-cell reactivity

Country Status (13)

Country Link
US (1) US8263090B2 (en)
EP (2) EP1768996B1 (en)
JP (1) JP5149002B2 (en)
CN (2) CN103467583A (en)
AT (1) ATE432944T1 (en)
AU (1) AU2005263477B2 (en)
BR (1) BRPI0513504B1 (en)
CA (2) CA2574449C (en)
DE (2) DE102004035337A1 (en)
ES (1) ES2328050T3 (en)
PT (1) PT1768996E (en)
RU (1) RU2409589C2 (en)
WO (1) WO2006008018A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT503690A1 (en) 2006-06-09 2007-12-15 Biomay Ag HYPOALLERGENIC MOLECULES
JP5746053B2 (en) 2009-02-05 2015-07-08 サーカッシア リミテッド Vaccine peptide
WO2011085782A1 (en) * 2010-01-14 2011-07-21 Merck Patent Gmbh Variants of the group-6 allergens of the poaceae with reduced allergenicity by mutagenesis of proline residues
CN108728450B (en) * 2018-06-11 2021-06-01 中国科学院武汉植物园 Gene CdERF1 significantly induced by low temperature in cynodon dactylon and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787150A1 (en) * 1994-10-25 1997-08-06 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
AR020102A1 (en) * 1998-07-30 2002-04-10 Ucb Sa COMPOSITE FOR THE PREVENTION AND / OR TREATMENT OF ALLERGY; PHARMACEUTICAL COMPOSITION, COSMETIC COMPOSITION, COMPOSITION IN THE FORM OF DRINK, FOOD AND / OR FOOD FOR DOMESTIC ANIMALS THAT INCLUDES IT AND USE OF SUCH COMPOUND OR SUCH PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A FOOD
AUPR779201A0 (en) 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
BRPI0313613B1 (en) * 2002-08-19 2016-06-07 Merck Patent Ges Mit Beschränkter Haftung variants of the major timothy grass phl p 1 allergen, their folding forms lm and hm, their uses and their preparation and purification processes, DNA molecule, recombinant DNA expression vector and its use, and pharmaceutical compositions

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DE WEERD N ET AL:: "Effect of cysteine mutagenesis on human IgE reactivity of recombinant forms of the major rye grass pollen allergen Lol p 1", ALLERGOLOGY INTERNATIONAL, vol. 52, no. 4, 1 December 2003 (2003-12-01), pages 183 - 190, XP002509719 *
LIN Z W ET AL: "Mapping of epitopes on Poa p I and Lol p I allergens with monoclonal antibodies.", INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY 1990, vol. 91, no. 3, 1990, pages 217 - 223, XP009117655, ISSN: 0020-5915 *
OLSEN E ET AL: "SYNTHESIS OF A RECOMBINANT POA P 1 ALLERGEN AND CHARACTERIZATION OF ITS ALLERGENIC EPITOPES", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 85, no. 1 PART 2, 1990, & FORTY-SIXTH ANNUAL MEETING OF THE AMERICAN ACADEMY OF ALLERGY AND IMMUNOLOGY, BALTIMORE, MARYLAND, U, pages 168, XP009117663, ISSN: 0091-6749 *
PETERSEN A ET AL: "Post-translational modifications influence IgE reactivity to the major allergen Phl p 1 of timothy grass pollen.", CLINICAL AND EXPERIMENTAL ALLERGY : JOURNAL OF THE BRITISH SOCIETY FOR ALLERGY AND CLINICAL IMMUNOLOGY. MAR 1998, vol. 28, no. 3, March 1998 (1998-03-01), pages 315 - 321, XP002351773, ISSN: 0954-7894 *
SCHRAMM G ET AL: "Allergen engineering: variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity", JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 162, no. 4, 15 February 1999 (1999-02-15), pages 2406 - 2414, XP002216586, ISSN: 0022-1767 *
SMITH A M ET AL: "REDUCTION IN IGE BINDING TO ALLERGEN VARIANTS GENERATED BY SITE-DIRECTED MUTAGENESIS: CONTRIBUTION OF DISULFIDE BONDS TO THE ANTIGENIC STRUCTURE OF THE MAJOR HOUSE DUST MITE ALLERGEN DER P 2", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 33, no. 4/5, 1996, pages 399 - 405, XP001010204, ISSN: 0161-5890 *
TAKAI T ET AL: "ENGINEERING OF THE MAJOR HOUSE DUST MITE ALLERGEN DER F2 FOR ALLERGEN-SPECIFIC IMMUNOTHERAPY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 15, 15 August 1997 (1997-08-15), pages 754 - 758, XP000783948, ISSN: 1087-0156 *
TAMBORINI ELENA ET AL: "Biochemical and immunological characterization of recombinant allergen Lol p 1", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 249, no. 3, November 1997 (1997-11-01), pages 886 - 894, XP002509720, ISSN: 0014-2956 *

Also Published As

Publication number Publication date
CA2574449A1 (en) 2006-01-26
PT1768996E (en) 2009-09-07
BRPI0513504A (en) 2008-05-06
CN1989151A (en) 2007-06-27
CA2574449C (en) 2015-12-01
AU2005263477A1 (en) 2006-01-26
RU2007106170A (en) 2008-08-27
BRPI0513504B1 (en) 2016-08-16
DE502005007428D1 (en) 2009-07-16
ES2328050T3 (en) 2009-11-06
US8263090B2 (en) 2012-09-11
DE102004035337A1 (en) 2006-03-16
RU2409589C2 (en) 2011-01-20
EP1768996B1 (en) 2009-06-03
CN103467583A (en) 2013-12-25
EP2028189A2 (en) 2009-02-25
US20080267985A1 (en) 2008-10-30
AU2005263477B2 (en) 2011-12-08
JP2008507262A (en) 2008-03-13
CA2903726A1 (en) 2006-01-26
EP1768996A1 (en) 2007-04-04
JP5149002B2 (en) 2013-02-20
WO2006008018A1 (en) 2006-01-26
ATE432944T1 (en) 2009-06-15
CN1989151B (en) 2014-08-27

Similar Documents

Publication Publication Date Title
Antico et al. Anaphylaxis by latex sublingual immunotherapy
Incorvaia et al. Importance of patient’s education in favouring compliance with sublingual immunotherapy
WO2001066136A3 (en) Microbial delivery system
WO2008123999A3 (en) Anti-ige antibodies
EP2322202A3 (en) Compositions and methods for the treatment of immune diseases
WO2004083249A3 (en) Antibodies against human il-21 receptor and uses therefor
Kondo et al. Identification and characterization of the allergens in the tomato fruit by immunoblotting
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
EP2028189A3 (en) Variants of group 1 allergens made of poaceae with reduced allergenicity and received T-cell reactivity
WO2008116149A3 (en) Apoptotic anti- ige antibodies binding the membrane-bound ige
Cabrera et al. Food allergy and the oral immunotherapy approach
Kim et al. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children
CA2789174C (en) Process for producing an allergen extract
Gaur et al. Guidelines for practice of allergen immunotherapy in India: 2017-An update
Metz-Favre et al. Molecular allergology in practice: an unusual case of LTP allergy
PL335981A1 (en) Modified recombinative alegenes of gramminae pollen for use in specific immunotherapy, method of obtaining them and their application
WO2009081440A3 (en) Allergens and allergoids from bee venom
EP2172215A3 (en) Hypoallergenic variants of the major allergen from Betula verrucosa pollen
Bohle T lymphocytes and food allergy
Leon et al. The major allergen of linseed.
US20180092929A1 (en) Methods for Suppressing Allergic Reactions
ATE290081T1 (en) PARIETARIA JUDAICA NS-LTP ANTIGEN VARIANTS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
Lee Oral immunotherapy for the treatment of immediate type food allergy
Ebo et al. Scampi allergy: from fancy name-giving to correct diagnosis
RU2809823C2 (en) Methods of cleaning allergen extract

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080807

AC Divisional application: reference to earlier application

Ref document number: 1768996

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20110429

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110910